Prevention of measles, mumps and rubella: 40 years of global experience with M-M-R_II

References

• Centers for Disease Control and Prevention. Measles. In: Hall E, Wodi AP, Hamborsky J, et al., editors. Epidemiology and prevention of vaccine-preventable diseases. 14th ed. Washington, D.C: Public Health Foundation; 2021.
   Google Scholar
• Centers for Disease Control and Prevention. Mumps. In: Hall E, Wodi AP, Hamborsky J, et al., editors. Epidemiology and prevention of vaccine-preventable diseases. 14th ed. Washington, D.C: Public Health Foundation;2021.
   Google Scholar
• Centers for Disease Control and Prevention. Rubella. In: Hall E, Wodi AP, Hamborsky J, et al., editors. Epidemiology and prevention of vaccine-preventable diseases. 14th ed. Washington, D.C: Public Health Foundation; 2021.
   Google Scholar
• World Health Organization. Mumps virus vaccines: WHO position paper. Wkly Epidemiol Rec. 2007;82:49–60.
   Google Scholar
• World Health Organization. Measles vaccines: WHO position paper - April 2017. Wkly Epidemiol Rec. 2017;92:205–28.
   PubMedGoogle Scholar
• World Health Organization. Measles. [ accessed 2021 Apr]. https://www.who.int/news-room/fact-sheets/detail/measles.
   Google Scholar
• World Health Organization. Rubella vaccines: WHO position paper - July 2020. Wkly Epidemiol Rec. 2020;95:306–24.
   Google Scholar
• Lievano F, Galea SA, Thornton M, Wiedmann RT, Manoff SB, Tran TN, Amin MA, Seminack MM, Vagie KA, Dana A, et al. Measles, mumps, and rubella virus vaccine (M-M-RII): a review of 32 years of clinical and postmarketing experience. Vaccine. 2012 Nov 6;30(48):6918–26. doi:10.1016/j.vaccine.2012.08.057.
   PubMed Web of Science ®Google Scholar
• Offit PA. Vaccinated: one man’s quest to defeat the World’s deadliest diseases. New York: Harper Collins; 2008.
   Google Scholar
• Hilleman MR. Past, present, and future of measles, mumps, and rubella virus vaccines. Pediatrics. 1992 July;90(1 Pt 2):149–53.
   PubMed Web of Science ®Google Scholar
• World Health Organization. List of prequalified vaccines. [ accessed 2021 Apr]. https://extranet.who.int/pqweb/vaccines/list-prequalified-vaccines.
   Google Scholar
• Bloch AB, Orenstein WA, Stetler HC, Wassilak SG, Amler RW, Bart KJ, Kirby CD, Hinman AR. Health impact of measles vaccination in the United States. Pediatrics. 1985 Oct;76(4):524–32.
   PubMed Web of Science ®Google Scholar
• National Communicable Disease Center. Rubella surveillance. Bethesda (MD): US Department of Health, Education, and Welfare; 1969.
   Google Scholar
• Watson JC, Hadler SC, Dykewicz CA, Reef S, Phillips L. Measles, mumps, and rubella–vaccine use and strategies for elimination of measles, rubella, and congenital rubella syndrome and control of mumps: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 1998 May 22;47(RR–8):1–57.
   PubMedGoogle Scholar
• Centers for Disease Control and Prevention. Appendix E: data and statistics. In: Epidemiology and prevention of vaccine-preventable diseases. Washington, D.C. Public Health Foundation, 2015.
   Google Scholar
• Roush SW, Murphy TV, Vaccine-Preventable Disease Table Working G. Historical comparisons of morbidity and mortality for vaccine-preventable diseases in the United States. JAMA. 2007 Nov 14;298(18):2155–63. doi:10.1001/jama.298.18.2155.
   PubMed Web of Science ®Google Scholar
• Katz SL, Hinman AR. Summary and conclusions: measles elimination meeting, 16-17 March 2000. J Infect Dis. 2004 May 1;189(Suppl 1):S43–47. doi:10.1086/377696.
   PubMed Web of Science ®Google Scholar
• Papania MJ, Wallace GS, Rota PA, Icenogle JP, Fiebelkorn AP, Armstrong GL, Reef SE, Redd SB, Abernathy ES, Barskey AE, et al. Elimination of endemic measles, rubella, and congenital rubella syndrome from the Western hemisphere: the US experience. JAMA Pediatr. 2014 Feb;168(2):148–55. doi:10.1001/jamapediatrics.2013.4342.
   PubMed Web of Science ®Google Scholar
• Reef SE, Cochi SL. The evidence for the elimination of rubella and congenital rubella syndrome in the United States: a public health achievement. Clin Infect Dis. 2006 Nov 1;43(Suppl 3):S123–125. doi:10.1086/505943.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention (CDC) Elimination of rubella and congenital rubella syndrome — United States, 1969–2004. MMWR Morb Mortal Wkly Rep. 2005 Mar;54(11):279–82.
   PubMedGoogle Scholar
• World Health Organization. Ten threats to global health in 2019. https://www.who.int/news-room/spotlight/ten-threats-to-global-health-in-2019. Accessed 16 December 2021.
   Google Scholar
• Hough-Telford C, Kimberlin DW, Aban I, Hitchcock WP, Almquist J, Kratz R, OConnor KG. Vaccine delays, refusals, and patient dismissals: a survey of pediatricians. Pediatrics. 2016 Sept;138(3). doi:10.1542/peds.2016-2127.
   PubMed Web of Science ®Google Scholar
• Kempe A, Saville AW, Albertin C, Zimet G, Breck A, Helmkamp L, Vangala S, Dickinson LM, Rand C, Humiston S, et al. Parental hesitancy about routine childhood and influenza vaccinations: a national survey. Pediatrics. 2020 July;146(1). doi:10.1542/peds.2019-3852.
   PubMed Web of Science ®Google Scholar
• McKee C, Bohannon K. Exploring the reasons behind parental refusal of vaccines. J Pediatr Pharmacol Ther. 2016 Mar-Apr;21(2):104–09. doi:10.5863/1551-6776-21.2.104.
   PubMedGoogle Scholar
• Ventola CL. Immunization in the United States: recommendations, barriers, and measures to improve compliance: part 1: childhood vaccinations. P T. 2016 July;41(7):426–36.
   PubMedGoogle Scholar
• Balbi AM, Van Sant AA, Bean EW, Jacoby JL. Mumps: resurgence of a once-dormant disease. JAAPA. 2018 May;31(5):19–22. doi:10.1097/01.JAA.0000532112.90755.41.
   PubMedGoogle Scholar
• Feemster KA, Szipszky C. Resurgence of measles in the United States: how did we get here? Curr Opin Pediatr. 2020 Feb;32(1):139–44. doi:10.1097/MOP.0000000000000845.
   PubMed Web of Science ®Google Scholar
• Koh HK, Gellin BG. Measles as metaphor-what resurgence means for the future of immunization. JAMA. 2020 Mar 10;323(10):914–15. doi:10.1001/jama.2020.1372.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. Global measles outbreaks. https://www.cdc.gov/globalhealth/measles/data/global-measles-outbreaks.html. Accessed 16 December 2021.
   Google Scholar
• Patel MK, Goodson JL, Alexander JP Jr., Kretsinger K, Sodha SV, Steulet C, Gacic-Dobo M, Rota PA, McFarland J, Menning L, et al. Progress toward regional measles elimination - worldwide, 2000-2019. MMWR Morb Mortal Wkly Rep. 2020 Nov 13;69(45):1700–05. doi:10.15585/mmwr.mm6945a6.
   PubMed Web of Science ®Google Scholar
• Patel M, Lee AD, Redd SB, Clemmons NS, McNall RJ, Cohn AC, Gastañaduy PA. Increase in measles cases - United States, January 1-April 26, 2019. MMWR Morb Mortal Wkly Rep. 2019 May 3;68(17):402–04. doi:10.15585/mmwr.mm6817e1.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Measles – european Region. Disease outbreak news - update, 6 May 2019; 2019.
   Google Scholar
• National Foundation for Infectious Diseases. Issue brief: the impact of COVID-19 on US vaccination rates. https://www.nfid.org/keep-up-the-rates/issue-brief-the-impact-of-covid-19-on-us-vaccination-rates/. Accessed 16 December 2021.
   Google Scholar
• Centers for Disease Control and Prevention. Information for pediatric healthcare providers. https://www.cdc.gov/coronavirus/2019-ncov/hcp/pediatric-hcp.html. Accessed 16 December 2021.
   Google Scholar
• Guerra FM, Bolotin S, Lim G, Heffernan J, Deeks SL, Li Y, Crowcroft NS. The basic reproduction number (cit0) of measles: a systematic review. Lancet Infect Dis. 2017 Dec;17(12):e420–e428. doi:10.1016/S1473-3099(17)30307-9.
   PubMed Web of Science ®Google Scholar
• Our World in Data. The current case fatality rate of COVID-19. [ accessed 2021 Feb 19]. https://ourworldindata.org/mortality-risk-covid#the-current-case-fatality-rate-of-covid-19.
   Google Scholar
• Rajgor DD, Lee MH, Archuleta S, Bagdasarian N, Quek SC. The many estimates of the COVID-19 case fatality rate. Lancet Infect Dis. 2020 July;20(7):776–77. doi:10.1016/S1473-3099(20)30244-9.
   PubMed Web of Science ®Google Scholar
• Sanche S, Lin YT, Xu C, Romero-Severson E, Hengartner N, Ke R. High contagiousness and rapid spread of severe acute respiratory syndrome coronavirus 2. Emerg Infect Dis. 2020 July;26(7):1470–77. doi:10.3201/eid2607.200282.
   PubMed Web of Science ®Google Scholar
• Santoli JM, Lindley MC, DeSilva MB, Kharbanda EO, Daley MF, Galloway L, Gee J, Glover M, Herring B, Kang Y, et al. Effects of the COVID-19 pandemic on routine pediatric vaccine ordering and administration - United States, 2020. MMWR Morb Mortal Wkly Rep. 2020 May 15;69(19):591–93. doi:10.15585/mmwr.mm6919e2.
   PubMed Web of Science ®Google Scholar
• World Health Organization. WHO and UNICEF warn of a decline in vaccinations during COVID-19. https://www.who.int/news/item/15-07-2020-who-and-unicef-warn-of-a-decline-in-vaccinations-during-covid-19. Accessed 16 December 2021.
   Google Scholar
• World Health Organization. Worldwide measles deaths climb 50% from 2016 to 2019 claiming over 207 500 lives in 2019. 2020.
   Google Scholar
• Billah MA, Miah MM, Khan MN. Reproductive number of coronavirus: a systematic review and meta-analysis based on global level evidence. PLoS One. 2020;15(11):e0242128. doi:10.1371/journal.pone.0242128.
   PubMed Web of Science ®Google Scholar
• Nyaku M, Richardson E, Martinon-Torres F, Kuter BJ. Evaluation of the safety and immunogenicity of M-M-RII (combination measles-mumps-rubella vaccine): clinical trials of healthy children and adults published between 2010 and 2019. Pediatr Infect Dis J. 2021 July 22;40:1046–54. doi:10.1097/INF.0000000000003273.
   PubMed Web of Science ®Google Scholar
• Pawaskar M, Schmidt E, Marshall GS, Fergie J, Richardson E, Saldutti LP, Li S, Neumann M, Koller L, Kuter B, et al. Use of M-M-R II outside of the routinely recommended age range - a systematic literature review. Hum Vaccin Immunother. 2021 June 15;1–7. doi:10.1080/21645515.2021.1933874.
   PubMed Web of Science ®Google Scholar
• Kuter BJ, Brown M, Wiedmann RT, Hartzel J, Musey L. Safety and immunogenicity of M-M-RII (combination measles-mumps-rubella vaccine) in clinical trials of healthy children conducted between 1988 and 2009. Pediatr Infect Dis J. 2016 Sept;35(9):1011–20. doi:10.1097/INF.0000000000001241.
   PubMed Web of Science ®Google Scholar
• Khalil M, Poltera AA, Al-howasi M, Herzog C, Gerike E, Wegmüller B, Glück R. Response to measles revaccination among toddlers in Saudi Arabia by the use of two different trivalent measles-mumps-rubella vaccines. Trans R Soc Trop Med Hyg. 1999 Mar-Apr;93(2):214–19. doi:10.1016/S0035-9203(99)90310-3.
   PubMed Web of Science ®Google Scholar
• Berry AA, Abu-Elyazeed R, Diaz-Perez C, Mufson MA, Harrison CJ, Leonardi M, Twiggs JD, Peltier C, Grogg S, Carbayo A, et al. Two-year antibody persistence in children vaccinated at 12-15 months with a measles-mumps-rubella virus vaccine without human serum albumin. Hum Vaccin Immunother. 2017 July 3;13(7):1516–22. doi:10.1080/21645515.2017.1309486.
   PubMed Web of Science ®Google Scholar
• Black S, Friedland LR, Ensor K, Weston WM, Howe B, Klein NP. Diphtheria-tetanus-acellular pertussis and inactivated poliovirus vaccines given separately or combined for booster dosing at 4-6 years of age. Pediatr Infect Dis J. 2008 Apr;27(4):341–46. doi:10.1097/INF.0b013e3181616180.
   PubMed Web of Science ®Google Scholar
• Black S, Friedland LR, Schuind A, Howe B, GlaxoSmithKline D-IPVVSG. Immunogenicity and safety of a combined DTaP-IPV vaccine compared with separate DTaP and IPV vaccines when administered as pre-school booster doses with a second dose of MMR vaccine to healthy children aged 4-6 years. Vaccine. 2006 Aug 28;24(35–36):6163–71. doi:10.1016/j.vaccine.2006.04.001.
   PubMed Web of Science ®Google Scholar
• Black SB, Cimino CO, Hansen J, Lewis E, Ray P, Corsaro B, Graepel J, Laufer D. Immunogenicity and safety of measles-mumps-rubella, varicella and Haemophilus influenzae type b vaccines administered concurrently with a fourth dose of heptavalent pneumococcal conjugate vaccine compared with the vaccines administered without heptavalent pneumococcal conjugate vaccine. Pediatr Infect Dis J. 2006 Apr;25(4):306–11. doi:10.1097/01.inf.0000207409.92198.6f.
   PubMed Web of Science ®Google Scholar
• Bryant K, McVernon J, Marchant C, Nolan T, Marshall G, Richmond P, Marshall H, Nissen M, Lambert S, Aris E, et al. Immunogenicity and safety of measles-mumps-rubella and varicella vaccines coadministered with a fourth dose of Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine in toddlers: a pooled analysis of randomized trials. Hum Vaccin Immunother. 2012 Aug;8(8):1036–41. doi:10.4161/hv.20357.
   PubMed Web of Science ®Google Scholar
• Bryant KA, Gurtman A, Girgenti D, Reisinger K, Johnson A, Pride MW, Patterson S, Devlin C, Gruber WC, Emini EA, et al. Antibody responses to routine pediatric vaccines administered with 13-valent pneumococcal conjugate vaccine. Pediatr Infect Dis J. 2013 Apr;32(4):383–88. doi:10.1097/INF.0b013e318279e9a9.
   PubMed Web of Science ®Google Scholar
• Cassidy WM, Jones G, Williams K, Deforest A, Forghani B, Virella G, Venters C. Safety and immunogenicity of concomitant versus nonconcomitant administration of hepatitis B, tetanus-diphtheria, and measles-mumps-rubella vaccines in healthy eleven- to twelve-year-olds. J Adolesc Health. 2005 Mar;36(3):187–92. doi:10.1016/j.jadohealth.2004.02.021.
   PubMed Web of Science ®Google Scholar
• Deforest A, Long SS, Lischner HW, Girone JA, Clark JL, Srinivasan R, Maguire TG, Diamond SA, Schiller RP, Rothstein EP, et al. Simultaneous administration of measles-mumps-rubella vaccine with booster doses of diphtheria-tetanus-pertussis and poliovirus vaccines. Pediatrics. 1988 Feb;81(2):237–46.
   PubMed Web of Science ®Google Scholar
• Englund JA, Suarez CS, Kelly J, Tate DY, Balfour HH Jr. Placebo-controlled trial of varicella vaccine given with or after measles-mumps-rubella vaccine. J Pediatr. 1989 Jan;114(1):37–44. doi:10.1016/S0022-3476(89)80598-0.
   PubMed Web of Science ®Google Scholar
• Ferrera G, Gajdos V, Thomas S, Tran C, Fiquet A. Safety of a refrigerator-stable varicella vaccine (VARIVAX) in healthy 12- to 15-month-old children: a randomized, double-blind, cross-over study. Hum Vaccin. 2009 July;5(7):455–60. doi:10.4161/hv.8269.
   PubMed Web of Science ®Google Scholar
• Gatchalian S, Leboulleux D, Desauziers E, Bermal N, Borja-Tabora C. Immunogenicity and safety of a varicella vaccine, Okavax, and a trivalent measles, mumps and rubella vaccine, MMR-II, administered concomitantly in healthy Filipino children aged 12-24 months. Southeast Asian J Trop Med Public Health. 2003 Sept;34(3):589–97.
   PubMedGoogle Scholar
• Gillet Y, Habermehl P, Thomas S, Eymin C, Fiquet A. Immunogenicity and safety of concomitant administration of a measles, mumps and rubella vaccine (M-M-RvaxPro) and a varicella vaccine (VARIVAX) by intramuscular or subcutaneous routes at separate injection sites: a randomised clinical trial. BMC Med. 2009 Apr 14;7:16. doi:10.1186/1741-7015-7-16.
   PubMed Web of Science ®Google Scholar
• Guerra FA, Gress J, Werzberger A, Reisinger K, Walter E, Lakkis H, Grosso AD, Welebob C, Kuter BJ. Safety, tolerability and immunogenicity of VAQTA given concomitantly versus nonconcomitantly with other pediatric vaccines in healthy 12-month-old children. Pediatr Infect Dis J. 2006 Oct;25(10):912–19. doi:10.1097/01.inf.0000238135.01287.b9.
   PubMed Web of Science ®Google Scholar
• Hesley TM, Reisinger KS, Sullivan BJ, Jensen EH, Stasiorowski S, Meechan CD, Chan CY, West DJ. Concomitant administration of a bivalent Haemophilus influenzae type b-hepatitis B vaccine, measles-mumps-rubella vaccine and varicella vaccine: safety, tolerability and immunogenicity. Pediatr Infect Dis J. 2004 Mar;23(3):240–45. doi:10.1097/01.inf.0000114902.84651.02.
   PubMed Web of Science ®Google Scholar
• Huang LM, Lin TY, Chiu CH, Chiu N-C, Chen P-Y, Yeh S-J, Boaz M, Hutagalung Y, Bouckenooghe A, Feroldi E, et al. Concomitant administration of live attenuated Japanese encephalitis chimeric virus vaccine (JE-CV) and measles, mumps, rubella (MMR) vaccine: randomized study in toddlers in Taiwan. Vaccine. 2014 Sept 15;32(41):5363–69. doi:10.1016/j.vaccine.2014.02.085.
   PubMed Web of Science ®Google Scholar
• Klein NP, Abu-Elyazeed R, Povey M, Macias Parra M, Diez-Domingo J, Ahonen A, Korhonen T, Tinoco J-C, Weiner L, Marshall GS, et al. Immunogenicity and safety of a measles-mumps-rubella vaccine administered as a first dose to children aged 12 to 15 months: a phase III, randomized, noninferiority, lot-to-lot consistency study. J Pediatric Infect Dis Soc. 2020 Apr 30;9(2):194–201. doi:10.1093/jpids/piz010.
   PubMed Web of Science ®Google Scholar
• Klein NP, Weston WM, Kuriyakose S, Kolhe D, Howe B, Friedland LR, Van Der Meeren O. An open-label, randomized, multi-center study of the immunogenicity and safety of DTaP-IPV (Kinrix) co-administered with MMR vaccine with or without varicella vaccine in healthy pre-school age children. Vaccine. 2012 Jan 11;30(3):668–74. doi:10.1016/j.vaccine.2011.10.065.
   PubMed Web of Science ®Google Scholar
• Lieberman JM, Williams WR, Miller JM, Black S, Shinefield H, Henderson F, Marchant CD, Werzberger A, Halperin S, Hartzel J, et al. The safety and immunogenicity of a quadrivalent measles, mumps, rubella and varicella vaccine in healthy children: a study of manufacturing consistency and persistence of antibody. Pediatr Infect Dis J. 2006 July;25(7):615–22. doi:10.1097/01.inf.0000220209.35074.0b.
   PubMed Web of Science ®Google Scholar
• Lu MY, Huang LM, Lee CY, Lee PI, Chiu HH, Tsai HY. Evaluation of a live attenuated varicella vaccine in 15- to 18-month-old healthy children. Zhonghua Min Guo Xiao Er Ke Yi Xue Hui Za Zhi. 1998 Jan-Feb;39(1):38–42.
   PubMedGoogle Scholar
• MMR Study Group 158. A second dose of a measles-mumps-rubella vaccine administered to healthy four-to-six-year-old children: a phase III, observer-blind, randomized, safety and immunogenicity study comparing GSK MMR and MMR II with and without DTaP-IPV and varicella vaccines co-administration. Hum Vaccin Immunother. 2019;15(4):786–99.
   PubMed Web of Science ®Google Scholar
• MMR Study Group 161. Immunogenicity and safety of measles-mumps-rubella vaccine at two different potency levels administered to healthy children aged 12-15months: a phase III, randomized, non-inferiority trial. Vaccine. 2018 Sept 11;36(38):5781–88. doi:10.1016/j.vaccine.2018.07.076.
   PubMed Web of Science ®Google Scholar
• MMR Study Group 162. Safety and immunogenicity of an upper-range release titer measles-mumps-rubella vaccine in children vaccinated at 12 to 15 months of age: a phase III, randomized study. Hum Vaccin Immunother. 2018;14(12):2921–31. doi:10.1080/21645515.2018.1502527.
   PubMed Web of Science ®Google Scholar
• Mufson MA, Diaz C, Leonardi M, Harrison CJ, Grogg S, Carbayo A, Carlo-Torres S, JeanFreau R, Quintero-Del-Rio A, Bautista G, et al. Safety and immunogenicity of human serum albumin-free MMR vaccine in US children aged 12-15 months. J Pediatric Infect Dis Soc. 2015 Dec;4(4):339–48. doi:10.1093/jpids/piu081.
   PubMed Web of Science ®Google Scholar
• Nolan T, Bernstein DI, Block SL, Hilty M, Keyserling HL, Marchant C, Marshall H, Richmond P, Yogev R, Cordova J, et al. Safety and immunogenicity of concurrent administration of live attenuated influenza vaccine with measles-mumps-rubella and varicella vaccines to infants 12 to 15 months of age. Pediatrics. 2008 Mar;121(3):508–16. doi:10.1542/peds.2007-1064.
   PubMed Web of Science ®Google Scholar
• Perrett KP, Snape MD, Ford KJ, John TM, Yu LMM, Langley JM, McNeil S, Dull PM, Ceddia F, Anemona A, et al. Immunogenicity and immune memory of a nonadjuvanted quadrivalent meningococcal glycoconjugate vaccine in infants. Pediatr Infect Dis J. 2009 Mar;28(3):186–93. doi:10.1097/INF.0b013e31818e037d.
   PubMed Web of Science ®Google Scholar
• Reisinger KS, Brown ML, Xu J, Sullivan BJ, Marshall GS, Nauert B, Matson DO, Silas PE, Schödel F, Gress JO, et al. A combination measles, mumps, rubella, and varicella vaccine (ProQuad) given to 4- to 6-year-old healthy children vaccinated previously with M-M-RII and varivax. Pediatrics. 2006 Feb;117(2):265–72. doi:10.1542/peds.2005-0092.
   PubMed Web of Science ®Google Scholar
• Reisinger KS, Richardson E, Malacaman EA, Levin MJ, Gardner JL, Wang W, Stek JE, Kuter B. A double-blind, randomized, controlled, multi-center safety and immunogenicity study of a refrigerator-stable formulation of VARIVAX(R). Vaccine. 2019 Sept 10;37(38):5788–95. doi:10.1016/j.vaccine.2018.01.089.
   PubMed Web of Science ®Google Scholar
• Reuman PD, Sawyer MH, Kuter BJ, Matthews H. Safety and immunogenicity of concurrent administration of measles-mumps-rubella-varicella vaccine and PedvaxHIB vaccines in healthy children twelve to eighteen months old. The MMRV Study Group. Pediatr Infect Dis J. 1997 July;16(7):662–67. doi:10.1097/00006454-199707000-00008.
   PubMed Web of Science ®Google Scholar
• Rinderknecht S, Bryant K, Nolan T, Pavia-Ruz N, Doniz CA, Weber MAR, Cohen C, Aris E, Mesaros N, Miller JM, et al. The safety profile of Haemophilus influenzae type b– neisseria meningitidis serogroups C and Y tetanus toxoid conjugate vaccine (HibMenCY). Hum Vaccin Immunother. 2012 Mar;8(3):304–11. doi:10.4161/hv.18752.
   PubMed Web of Science ®Google Scholar
• Rinderknecht S, Michaels MG, Blatter M, Gaglani M, Andrews W, Abughali N, Chandreshekaran V, Trofa AF. Immunogenicity and safety of an inactivated hepatitis A vaccine when coadministered with measles-mumps-rubella and varicella vaccines in children less than 2 years of age. Pediatr Infect Dis J. 2011 Oct;30(10):e179–185. doi:10.1097/INF.0b013e31822256a5.
   PubMed Web of Science ®Google Scholar
• Rothstein EP, Bernstein HH, Glode MP, Laussucq S, Nonenmacher J, Long SS, Hackell JG. Simultaneous administration of a diphtheria and tetanus toxoids and acellular pertussis vaccine with measles-mumps-rubella and oral poliovirus vaccines. Am J Dis Child. 1993 Aug;147(8):854–57. doi:10.1001/archpedi.1993.02160320056019.
   PubMedGoogle Scholar
• Senders SD, Bundick ND, Li J, Zecca C, Helmond FA. Evaluation of immunogenicity and safety of VARIVAX New Seed Process (NSP) in children. Hum Vaccin Immunother. 2018 Feb 1;14(2):442–49. doi:10.1080/21645515.2017.1388479.
   PubMed Web of Science ®Google Scholar
• Shinefield H, Black S, Digilio L, Reisinger K, Blatter M, Gress JO, Brown MLH, Eves KA, Klopfer SO, Schödel F, et al. Evaluation of a quadrivalent measles, mumps, rubella and varicella vaccine in healthy children. Pediatr Infect Dis J. 2005 Aug;24(8):665–69. doi:10.1097/01.inf.0000172902.25009.a1.
   PubMed Web of Science ®Google Scholar
• Shinefield H, Black S, Thear M, Coury D, Reisinger K, Rothstein E, Xu J, Hartzel J, Evans B, Digilio L, et al. Safety and immunogenicity of a measles, mumps, rubella and varicella vaccine given with combined Haemophilus influenzae type b conjugate/hepatitis B vaccines and combined diphtheria-tetanus-acellular pertussis vaccines. Pediatr Infect Dis J. 2006 Apr;25(4):287–92. doi:10.1097/01.inf.0000207857.10947.1f.
   PubMed Web of Science ®Google Scholar
• Shinefield H, Black S, Williams WR, Reisinger K, Stewart T, Meissner HC, Guerrero J, Klopfer SO, Schödel F, Kuter BJ, et al. Dose-response study of a quadrivalent measles, mumps, rubella and varicella vaccine in healthy children. Pediatr Infect Dis J. 2005 Aug;24(8):670–75. doi:10.1097/01.inf.0000172901.29621.e9.
   PubMed Web of Science ®Google Scholar
• Shinefield HR, Black SB, Staehle BO, Adelman T, Ensor K, Ngai A, White CJ, Bird SR, Matthews H, Kuter BJ, et al. Safety, tolerability and immunogenicity of concomitant injections in separate locations of M-M-R II, VARIVAX and TETRAMUNE in healthy children vs. concomitant injections of M-M-R II and TETRAMUNE followed six weeks later by VARIVAX. Pediatr Infect Dis J. 1998 Nov;17(11):980–85. doi:10.1097/00006454-199811000-00003.
   PubMed Web of Science ®Google Scholar
• Shinefield HR, Black SB, Staehle BO, Matthews H, Adelman T, Ensor K, Chan SLA, Heyse J, Waters M, Chan CY, et al. Vaccination with measles, mumps and rubella vaccine and varicella vaccine: safety, tolerability, immunogenicity, persistence of antibody and duration of protection against varicella in healthy children. Pediatr Infect Dis J. 2002 June;21(6):555–61. doi:10.1097/00006454-200206000-00014.
   PubMed Web of Science ®Google Scholar
• Snape MD, Perrett KP, Ford KJ, John TM, Pace D, Yu L-M, Langley JM, McNeil S, Dull PM, Ceddia F, et al. Immunogenicity of a tetravalent meningococcal glycoconjugate vaccine in infants: a randomized controlled trial. JAMA. 2008 Jan 9;299(2):173–84. doi:10.1001/jama.2007.29-c.
   PubMed Web of Science ®Google Scholar
• Watson BM, Laufer DS, Kuter BJ, Staehle B, White CJ, Starr SE. Safety and immunogenicity of a combined live attenuated measles, mumps, rubella, and varicella vaccine (MMR(II)V) in healthy children. J Infect Dis. 1996 Mar;173(3):731–34. doi:10.1093/infdis/173.3.731.
   PubMed Web of Science ®Google Scholar
• White CJ, Stinson D, Staehle B, Cho I, Matthews H, Ngai A, Keller P, Eiden J, Kuter B. Measles, mumps, rubella, and varicella combination vaccine: safety and immunogenicity alone and in combination with other vaccines given to children. Measles, mumps, rubella, varicella vaccine study group. Clin Infect Dis. 1997 May;24(5):925–31. doi:10.1093/clinids/24.5.925.
   PubMed Web of Science ®Google Scholar
• Halperin SA, McGrath P, Smith B, Houston T. Lidocaine-prilocaine patch decreases the pain associated with the subcutaneous administration of measles-mumps-rubella vaccine but does not adversely affect the antibody response. J Pediatr. 2000 June;136(6):789–94. doi:10.1016/S0022-3476(00)64169-0.
   PubMed Web of Science ®Google Scholar
• Abu-Elyazeed R, Jennings W, Severance R, Noss M, Caplanusi A, Povey M, Henry O. Immunogenicity and safety of a second dose of a measles-mumps-rubella vaccine administered to healthy participants 7 years of age or older: a phase III, randomized study. Hum Vaccin Immunother. 2018;14(11):2624–31. doi:10.1080/21645515.2018.1489186.
   PubMed Web of Science ®Google Scholar
• Diaz-Ortega JL, Bennett JV, Castaneda D, Vieyra JR, Valdespino-Gomez JL, de Castro JF. Successful seroresponses to measles and rubella following aerosolized Triviraten vaccine, but poor response to aerosolized mumps (Rubini) component: comparisons with injected MMR. Vaccine. 2010 Jan 8;28(3):692–98. doi:10.1016/j.vaccine.2009.10.083.
   PubMed Web of Science ®Google Scholar
• Diaz-Ortega JL, Bennett JV, Castaneda-Desales D, Quintanilla DM, Martinez D, de Castro JF. Booster immune response in children 6-7 years of age, randomly assigned to four groups with two MMR vaccines applied by aerosol or by injection. Vaccine. 2014 June 17;32(29):3680–86. doi:10.1016/j.vaccine.2014.04.031.
   PubMed Web of Science ®Google Scholar
• GlaxoSmithKline Biologicals. Phase II randomized, controlled study to evaluate immunogenicity, reactogenicity and safety of GlaxoSmithKline Biologicals’ combined Measles-Mumps-Rubella (Priorix™) vaccine produced using the Modified mumps Manufacturing Process and containing no HSA (Priorix-MMP-mp) compared to the currently licensed GlaxoSmithKline Biologicals’ Priorix™ and Merck and Co.’s M-M-R®II vaccines when administered as a primary vaccination to healthy children aged 12-24 months. Clinical Study Report for Study 209762 (MeMuRu-151) (Development Phase II). GSK Study ID: 209762/151. GSK Study Register; 2004.
   Google Scholar
• Merck Sharp & Dohme Corp. A study of ProQuad[TM] in healthy children in Korea (V221-023). 2017. ClinicalTrials.gov.
   Google Scholar
• Arciuolo RJ, Jablonski RR, Zucker JR, Rosen JB. Effectiveness of measles vaccination and immune globulin post-exposure prophylaxis in an outbreak setting-New York City, 2013. Clin Infect Dis. 2017 Nov 13;65(11):1843–47. doi:10.1093/cid/cix639.
   PubMed Web of Science ®Google Scholar
• Cardemil CV, Dahl RM, James L, Wannemuehler K, Gary HE, Shah M, Marin M, Riley J, Feikin DR, Patel M, et al. Effectiveness of a third dose of MMR vaccine for mumps outbreak control. N Engl J Med. 2017 Sept 7;377(10):947–56. doi:10.1056/NEJMoa1703309.
   PubMed Web of Science ®Google Scholar
• Cortese MM, Jordan HT, Curns AT, Quinlan P, Ens K, Denning P, Dayan G. Mumps vaccine performance among university students during a mumps outbreak. Clin Infect Dis. 2008 Apr 15;46(8):1172–80. doi:10.1086/529141.
   PubMed Web of Science ®Google Scholar
• De Serres G, Boulianne N, Defay F, Brousseau N, Benoît M, Lacoursière S, Guillemette F, Soto J, Ouakki M, Ward BJ, et al. Higher risk of measles when the first dose of a 2-dose schedule of measles vaccine is given at 12-14 months versus 15 months of age. Clin Infect Dis. 2012 Aug;55(3):394–402. doi:10.1093/cid/cis439.
   PubMed Web of Science ®Google Scholar
• Hersh BS, Fine PE, Kent WK, Cochi SL, Kahn LH, Zell ER, Hays PL, Wood CL. Mumps outbreak in a highly vaccinated population. J Pediatr. 1991 Aug;119(2):187–93. doi:10.1016/S0022-3476(05)80726-7.
   PubMed Web of Science ®Google Scholar
• Livingston KA, Rosen JB, Zucker JR, Zimmerman CM. Mumps vaccine effectiveness and risk factors for disease in households during an outbreak in New York City. Vaccine. 2014 Jan 9;32(3):369–74. doi:10.1016/j.vaccine.2013.11.021.
   PubMed Web of Science ®Google Scholar
• Lynn TV, Beller M, Funk EA, Middaugh JP, Ritter D, Rota RA, Bellini WJ, Torok TJ. Incremental effectiveness of 2 doses of measles-containing vaccine compared with 1 dose among high school students during an outbreak. J Infect Dis. 2004 May 1;189(Suppl 1):S86–90. doi:10.1086/377699.
   PubMed Web of Science ®Google Scholar
• Marin M, Quinlisk P, Shimabukuro T, Sawhney C, Brown C, Lebaron CW. Mumps vaccination coverage and vaccine effectiveness in a large outbreak among college students–Iowa, 2006. Vaccine. 2008 July 4;26(29–30):3601–07. doi:10.1016/j.vaccine.2008.04.075.
   PubMed Web of Science ®Google Scholar
• Nelson GE, Aguon A, Valencia E, Oliva R, Guerrero ML, Reyes R, Lizama A, Diras D, Mathew A, Camacho EJ, et al. Epidemiology of a mumps outbreak in a highly vaccinated island population and use of a third dose of measles-mumps-rubella vaccine for outbreak control–Guam 2009 to 2010. Pediatr Infect Dis J. 2013 Apr;32(4):374–80. doi:10.1097/INF.0b013e318279f593.
   PubMed Web of Science ®Google Scholar
• Ogbuanu IU, Kutty PK, Hudson JM, Blog D, Abedi GR, Goodell S, Lawler J, McLean HQ, Pollock L, Rausch-Phung E, et al. Impact of a third dose of measles-mumps-rubella vaccine on a mumps outbreak. Pediatrics. 2012 Dec;130(6):e1567–1574. doi:10.1542/peds.2012-0177.
   PubMed Web of Science ®Google Scholar
• Woudenberg T, van der Maas NAT, Knol MJ, de Melker H, van Binnendijk RS, Hahne SJM. Effectiveness of early measles, mumps, and rubella vaccination among 6-14-month-old infants during an epidemic in the netherlands: an observational cohort study. J Infect Dis. 2017 Apr 15;215(8):1181–87. doi:10.1093/infdis/jiw586.
   PubMed Web of Science ®Google Scholar
• Wiedmann RT, Reisinger KS, Hartzel J, Malacaman E, Senders SD, Giacoletti KED, Shaw E, Kuter BJ, Schödel F, Musey LK, et al. M-M-R(®)II manufactured using recombinant human albumin (rHA) and M-M-R(®)II manufactured using human serum albumin (HSA) exhibit similar safety and immunogenicity profiles when administered as a 2-dose regimen to healthy children. Vaccine. 2015 Apr 27;33(18):2132–40. doi:10.1016/j.vaccine.2015.03.017.
   PubMed Web of Science ®Google Scholar
• Brunell PA, Novelli VM, Lipton SV, Pollock B. Combined vaccine against measles, mumps, rubella, and varicella. Pediatrics. 1988 June;81(6):779–84.
   PubMed Web of Science ®Google Scholar
• Christenson B, Böttiger M, Heller L. Mass vaccination programme aimed at eradicating measles, mumps, and rubella in Sweden: first experience. Br Med J (Clin Res Ed). 1983 Aug 6;287(6389):389–91. doi:10.1136/bmj.287.6389.389.
   PubMed Web of Science ®Google Scholar
• Gatchalian S, Cordero-Yap L, Lu-Fong M, Soriano R, Ludan A, Chitour K, Bock HL. A randomized comparative trial in order to assess the reactogenicity and immunogenicity of a new measles mumps rubella (MMR) vaccine when given as a first dose at 12-24 months of age. Southeast Asian J Trop Med Public Health. 1999 Sept;30(3):511–17.
   PubMedGoogle Scholar
• Lee CY, Tang RB, Huang FY, Tang H, Huang LM, Bock HL. A new measles mumps rubella (MMR) vaccine: a randomized comparative trial for assessing the reactogenicity and immunogenicity of three consecutive production lots and comparison with a widely used MMR vaccine in measles primed children. Int J Infect Dis. 2002 Sept;6(3):202–09. doi:10.1016/S1201-9712(02)90112-8.
   PubMedGoogle Scholar
• Lerman SJ, Bollinger M, Brunken JM. Clinical and serologic evaluation of measles, mumps, and rubella (HPV-77: DE-5and RA 27/3) virus vaccines, singly and in combination. Pediatrics. 1981 July;68(1):18–22.
   PubMed Web of Science ®Google Scholar
• Schwarzer S, Reibel S, Lang AB, Struck MM, Finkel B, Gerike E, Tischer A, Gassner M, Glück R, Stück B, et al. Safety and characterization of the immune response engendered by two combined measles, mumps and rubella vaccines. Vaccine. 1998 Jan-Feb;16(2–3):298–304. doi:10.1016/S0264-410X(97)00174-6.
   PubMed Web of Science ®Google Scholar
• Stück B, Stehr K, Bock HL. Concomitant administration of varicella vaccine with combined measles, mumps, and rubella vaccine in healthy children aged 12 to 24 months of age. Asian Pac J Allergy Immunol. 2002 June;20(2):113–20.
   PubMed Web of Science ®Google Scholar
• Usonis V, Bakasenas V, Chitour K, Clemens R. Comparative study of reactogenicity and immunogenicity of new and established measles, mumps and rubella vaccines in healthy children. Infection. 1998 July-Aug;26(4):222–26. doi:10.1007/BF02962367.
   PubMed Web of Science ®Google Scholar
• Usonis V, Bakasenas V, Kaufhold A, Chitour K, Clemens R. Reactogenicity and immunogenicity of a new live attenuated combined measles, mumps and rubella vaccine in healthy children. Pediatr Infect Dis J. 1999 Jan;18(1):42–48. doi:10.1097/00006454-199901000-00011.
   PubMed Web of Science ®Google Scholar
• Vesikari T, Ala-Laurila EL, Heikkinen A, Terho A, D’Hondt E, André FE. Clinical trial of a new trivalent measles-mumps-rubella vaccine in young children. Am J Dis Child. 1984 Sept;138(9):843–47. doi:10.1001/archpedi.1984.02140470043013.
   PubMedGoogle Scholar
• Chandwani S, Beeler J, Li H, Audet S, Smith B, Moye J, Nalin D, Krasinski K. Safety and immunogenicity of early measles vaccination in children born to HIV-infected mothers in the United States: results of Pediatric AIDS Clinical Trials Group (PACTG) protocol 225. J Infect Dis. 2011 July;204(Suppl 1):S179–189. doi:10.1093/infdis/jicit089.
   PubMed Web of Science ®Google Scholar
• Peltola H, Heinonen OP. Frequency of true adverse reactions to measles-mumps-rubella vaccine. A double-blind placebo-controlled trial in twins. Lancet. 1986 Apr 26;1(8487):939–42. doi:10.1016/S0140-6736(86)91044-5.
   PubMed Web of Science ®Google Scholar
• Virtanen M, Peltola H, Paunio M, Heinonen OP. Day-to-day reactogenicity and the healthy vaccinee effect of measles-mumps-rubella vaccination. Pediatrics. 2000 Nov;106(5):E62. doi:10.1542/peds.106.5.e62.
   PubMed Web of Science ®Google Scholar
• Kanra G, Ceyhan M, Ozmert E. Reactogenicity and immunogenicity of a new measles-mumps-rubella vaccine containing RIT 4385 mumps virus strain in healthy Turkish children. Turk J Pediatr. 2000 Oct-Dec;42(4):275–77.
   PubMed Web of Science ®Google Scholar
• GlaxoSmithKline. Immunogenicity and safety study of GlaxoSmithKline (GSK) biologicals’ combined measles-mumps-rubella (MMR) vaccine in children in their second year of life. NCT01681992; 2012.
   Google Scholar
• Wood C, Von Baeyer CL, Bourrillon A, Dejos-Conant V, Clyti N, Abitbol V. Self-assessment of immediate post-vaccination pain after two different MMR vaccines administered as a second dose in 4- to 6-year-old children. Vaccine. 2004 Nov 25;23(2):127–31. doi:10.1016/j.vaccine.2004.08.029.
   PubMed Web of Science ®Google Scholar
• GlaxoSmithKline Biologicals. A phase IIIA, observer-blind, randomized study to evaluate non-inferiority of a second dose of GSK Biologicals’ measles-mumps-rubella vaccine vs. a second dose of Merck & Co., Inc.’s MMR vaccine when administered to healthy subjects seven years of age and older, Clinical Study Report for Study 115231(MMR-159). GSK Sponsor-ID: 115231; NCT02058563; Eudra CT 2011-003672-36; 2016.
   Google Scholar
• SmithKline Beecham Biologicals. A phase III, blinded, randomized, multicenter U.S. study evaluating the clinical consistency of three production lots of SmithKline Beecham Biologicals’ MMR vaccine (PRIORIX) and comparability of PRIORIX with Merck’s M-M-R II vaccine, administered to healthy children 12 to 18 months of age. Study Report 209762/136 (MeMuRu 136). GSK Study ID: 209762/136; 1999.
   Google Scholar
• GlaxoSmithKline Biologicals. Immunogenicity and safety study of GSK Biologicals Kinrix when coadministered with GSK biologicals varivax. EUCTR 2011-002946-11; 2011.
   Google Scholar
• Merck Sharp & Dohme Corp. Frozen ProQuad administered concomitantly versus nonconcomitantly with other pediatric vaccines. 2015.
   Google Scholar
• GlaxoSmithKline Biologicals. A phase IIIb, open, randomized, controlled, multicentr study of the immunogenicity and safety of GlaxoSmithKleine Biologicals’ inactivated hepatitis A vaccine (Havrix®) [720 El.U/0.5mL dose] administered on a 0, 6 month schedule concomitantly with Merck and Company, Inc. measles-mumps-rubella vaccine (M-M-R® II) and Merck and Company Inc. Varicella Vaccine (VARIVAX®) to healthy children months of age. Clinical Study Report for Study 208109/231 (HAV-231) (Development Phase IIIb). GSK Study ID: 208109/231; NCT00197015; 2018.
   Google Scholar
• Merck Sharp & Dohme Corp. Safety, tolerability, and immunogenicity of 3 frozen ProQuad consistency lots in healthy children (V221-012)(COMPLETED). NCT00985153; 2009.
   Google Scholar
• GlaxoSmithKline. Consistency study of GlaxoSmithKline (GSK) biologicals’ MMR vaccine (209762) (priorix) comparing immunogenicity and safety to Merck & Co., Inc.’s MMR vaccine (M-M-R II), in children 12 to 15 months of age. NCT01702428; 2012.
   Google Scholar
• GlaxoSmithKline Biologicals. A phase II, randomized, observer blind, controlled, multicenter study to assess immunogenicity and antibody persistence following vaccination with GSK’s candidate combined measles, mumps, and rubella vaccine (MMR) versus M-M-R® II as a first dose, both administered subcutaneously at 12-15 months of age, concomitantly with hepatitis a vaccine (HAV), varicella vaccine (VV) and pneumococcal conjugate vaccine (PCV) but at separate sites. Clinical Study Report for 111870 (MMR-157 PRI); 2012.
   Google Scholar
• GlaxoSmithKline. Immunogenicity and safety study of GlaxoSmithKline (GSK) biologicals’ combined measles-mumps-rubella (MMR) vaccine in subjects four to six years of age. NCT01621802; 2017.
   Google Scholar
• GlaxoSmithKline Biologicals. Open, randomized, phase II, clinical trial to compare the immunogenicity and safety of a booster dose of GSK Biologicals’ DTaP-IPV vaccine (Infanrix®-IPV) co-administered with a booster dose of Merck and Company’s M-M-R II, to that of separate injections of GSK Biologicals’ DTaP vaccine (Infanrix®), Aventis Pasteur’s IPV (IPOL®) and M-M-R II administered as booster doses to healthy children 4 to 6 years of age. Clinical Study Report for Study: 213503 (DTPa-IPV-047) 047. GSK Study ID: 213503/047, NCT00263692; 2005.
   Google Scholar
• Diaz Ortega JL, Castaneda D, Arellano Quintanilla DM, Martinez D, Trumbo SP, Fernandez de Castro J. Antibody persistence in children aged 6-7 years one year following booster immunization with two MMR vaccines applied by aerosol or by injection. Vaccine. 2017 May 25;35(23):3116–22. doi:10.1016/j.vaccine.2017.04.027.
   PubMed Web of Science ®Google Scholar
• Dos Santos BA, Ranieri TS, Bercini M, Schermann MT, Famer S, Mohrdieck R, Maraskin T, Wagner MB. An evaluation of the adverse reaction potential of three measles-mumps-rubella combination vaccines. Rev Panam Salud Publica. 2002;12(4):240–46. doi:10.1590/s1020-49892002001000004.
   PubMedGoogle Scholar
• Gothefors L, Bergstrom E, Backman M. Immunogenicity and reactogenicity of a new measles, mumps and rubella vaccine when administered as a second dose at 12 y of age. Scand J Infect Dis. 2001;33(7):545–49. doi:10.1080/00365540110026593.
   PubMedGoogle Scholar
• Sarno MJ, Blase E, Galindo N, Ramirez R, Schirmer CL, Trujillo-Juarez DF. Clinical immunogenicity of measles, mumps and rubella vaccine delivered by the Injex jet injector: comparison with standard syringe injection. Pediatr Infect Dis J. 2000 Sept;19(9):839–42. doi:10.1097/00006454-200009000-00006.
   PubMed Web of Science ®Google Scholar
• Wakefield AJ, Murch SH, Anthony A, Linnell J, Casson DM, Malik M, Berelowitz M, Dhillon AP, Thomson MA, Harvey P, et al. Ileal-lymphoid-nodular hyperplasia, non-specific colitis, and pervasive developmental disorder in children. Lancet. 1998 Feb 28;351(9103):637–41. doi:10.1016/S0140-6736(97)11096-0.
   PubMed Web of Science ®Google Scholar
• Flaherty DK. The vaccine-autism connection: a public health crisis caused by unethical medical practices and fraudulent science. Ann Pharmacother. 2011 Oct;45(10):1302–04. doi:10.1345/aph.1Q318.
   PubMed Web of Science ®Google Scholar
• Godlee F, Smith J, Marcovitch H. Wakefield’s article linking MMR vaccine and autism was fraudulent. BMJ. 2011 Jan 5;342:c7452. doi:10.1136/bmj.c7452.
   PubMed Web of Science ®Google Scholar
• Baird G, Pickles A, Simonoff E, Charman T, Sullivan P, Chandler S, Loucas T, Meldrum D, Afzal M, Thomas B, et al. Measles vaccination and antibody response in autism spectrum disorders. Arch Dis Child. 2008 Oct;93(10):832–37. doi:10.1136/adc.2007.122937.
   PubMed Web of Science ®Google Scholar
• Demicheli V, Rivetti A, Debalini MG, Di Pietrantonj C. Vaccines for measles, mumps and rubella in children. Cochrane Database Syst Rev. 2012 Feb 15;(2):CD004407. doi:10.1002/14651858.CD004407.pub3.
   PubMed Web of Science ®Google Scholar
• Hornig M, Briese T, Buie T, Bauman ML, Lauwers G, Siemetzki U, Hummel K, Rota PA, Bellini WJ, O’Leary JJ, et al. Lack of association between measles virus vaccine and autism with enteropathy: a case-control study. PLoS One. 2008 Sept 4;3(9):e3140. doi:10.1371/journal.pone.0003140.
   PubMed Web of Science ®Google Scholar
• Hviid A, Hansen JV, Frisch M, Melbye M. Measles, mumps, rubella vaccination and autism: a nationwide cohort study. Ann Intern Med. 2019 Apr 16;170(8):513–20. doi:10.7326/M18-2101.
   PubMed Web of Science ®Google Scholar
• Jain A, Marshall J, Buikema A, Bancroft T, Kelly JP, Newschaffer CJ. Autism occurrence by MMR vaccine status among US children with older siblings with and without autism. JAMA. 2015 Apr 21;313(15):1534–40. doi:10.1001/jama.2015.3077.
   PubMed Web of Science ®Google Scholar
• Mrozek-Budzyn D, Kieltyka A, Majewska R. Lack of association between measles-mumps-rubella vaccination and autism in children: a case-control study. Pediatr Infect Dis J. 2010 May;29(5):397–400. doi:10.1097/INF.0b013e3181c40a8a.
   PubMed Web of Science ®Google Scholar
• Angel JB, Walpita P, Lerch RA, Sidhu MS, Masurekar M, DeLellis RA, Noble JT, Syndman DR, Udem SA. Vaccine-associated measles pneumonitis in an adult with AIDS. Ann Intern Med. 1998 July 15;129(2):104–06. doi:10.7326/0003-4819-129-2-199807150-00007.
   PubMed Web of Science ®Google Scholar
• Bitnun A, Shannon P, Durward A, Rota PA, Bellini WJ, Graham C, Wang E, Ford‐Jones EL, Cox P, Becker L, et al. Measles inclusion-body encephalitis caused by the vaccine strain of measles virus. Clin Infect Dis. 1999 Oct;29(4):855–61. doi:10.1086/520449.
   PubMed Web of Science ®Google Scholar
• Monafo WJ, Haslam DB, Roberts RL, Zaki SR, Bellini WJ, Coffin CM. Disseminated measles infection after vaccination in a child with a congenital immunodeficiency. J Pediatr. 1994 Feb;124(2):273–76. doi:10.1016/S0022-3476(94)70318-3.
   PubMed Web of Science ®Google Scholar
• Weitzman S, Manson D, Wilson G, Allen U. Fever and respiratory distress in an 8-year-old boy receiving therapy for acute lymphoblastic leukemia. J Pediatr. 2003 June;142(6):714–21. doi:10.1067/mpd.2003.217.
   PubMed Web of Science ®Google Scholar
• Rodriguez-Nava G, Trelles-Garcia DP, Yanez-Bello MA, Imani-Ramos T, Trelles-Garcia DP, Bustamante-Soliz DS, Patiño-Salamea E. MMR vaccine adverse drug reactions reports in the CDC WONDER system, 1989-2019. Open Forum Infect Dis. 2020 Aug;7(8):ofaa211. doi:10.1093/ofid/ofaa211.
   PubMed Web of Science ®Google Scholar
• Redd SC, King GE, Heath JL, Forghani B, Bellini WJ, Markowitz LE. Comparison of vaccination with measles-mumps-rubella vaccine at 9, 12, and 15 months of age. J Infect Dis. 2004 May 1;189(Suppl 1):S116–122. doi:10.1086/378691.
   PubMed Web of Science ®Google Scholar
• Henry O, Klein NP, Povey M, Parra MM, Diez-Domingo J, Ahonen A, Abu-Elyazeed R, Korhonen T, Tinoco JC, Weiner L, et al. A randomized, consistency study comparing immunogenicity and safety of 2 vaccines against measles, mumps and rubella (MMR) administered to children 12–15 months of age. New Orleans (LA): Infectious Disease Week; 2016
   Google Scholar
• Pebody RG, Gay NJ, Hesketh LM, Vyse A, Morgan-Capner P, Brown DW, Litton P, Miller E. Immunogenicity of second dose measles-mumps-rubella (MMR) vaccine and implications for serosurveillance. Vaccine. 2002 Jan 15;20(7–8):1134–40. doi:10.1016/S0264-410X(01)00435-2.
   PubMed Web of Science ®Google Scholar
• Merck Sharp & Dohme Corp. A study of ProQuad in healthy 4 to 6 year old children (V221-014). NCT00985166; 2009.
   Google Scholar
• Diaz-Ortega JL, Bennett JV, Castaneda D, Martinez D, de Castro JF. Antibody persistence in young adults 1 year after MMR immunization by aerosol or by subcutaneous route. Vaccine. 2010 Oct 18;28(44):7228–32. doi:10.1016/j.vaccine.2010.08.055.
   PubMed Web of Science ®Google Scholar
• Dos Santos BA, Stralioto SM, Siqueira MM, Ranieri TS, Bercini M, Schermann MT, Wagner MB, Silveira TR. Prevalence of antibodies against measles, mumps, and rubella before and after vaccination of school-age children with three different triple combined viral vaccines, Rio Grande do Sul, Brazil, 1996. Rev Panam Salud Publica. 2006 Nov;20(5):299–306. doi:10.1590/s1020-49892006001000002.
   PubMed Web of Science ®Google Scholar
• Just M, Berger R, Glück R, Wegmann A. Evaluation of a combined vaccine against measles-mumps-rubella produced on human diploid cells. Dev Biol Stand. 1986;65:25–27.
   PubMedGoogle Scholar
• Markowitz LE, Albrecht P, Rhodes P, Demonteverde R, Swint E, Maes EF, Powell C, Patriarca PA. Changing levels of measles antibody titers in women and children in the United States: impact on response to vaccination. Kaiser permanente measles vaccine trial team. Pediatrics. 1996 Jan;97(1):53–58.
   PubMed Web of Science ®Google Scholar
• Marin M, Marlow M, Moore KL, Patel M. Recommendation of the advisory committee on immunization practices for use of a third dose of mumps virus–containing vaccine in persons at increased risk for mumps during an outbreak. MMWR Morb Mortal Wkly Rep. 2018;67:33–38. doi:10.15585/mmwr.mm6701a7.
   PubMed Web of Science ®Google Scholar